ClinicalTrials.gg
CompletedNCT02369653Updated Mar 8, 2022Results posted

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

A Phase 3 interventional study of Apixaban and No systemic anticoagulant prophylaxis in Lymphoma and Acute Lymphoblastic Leukemia, sponsored by Bristol-Myers Squibb. Completed at 96 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.

Enrollment
3rd of 39
512 · median 74
Started
2015
the only one that year
Phase 3
5 of 42
none open now
Registered
22nd of 42
by date

Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 3, and was the 22nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)

03

Conditions studied

  • Lymphoma
  • Acute Lymphoblastic Leukemia

Keywords

  • Anticoagulation
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • New diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia
  • Planned 3-4 drug systemic induction chemotherapy with a , vincristine and a single dose or multiple doses of asparaginase, with or without daunorubicin
  • Functioning Central Venous Access Device
  • Must be able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube
  • Males and females,age 1 year(365 days) to \< 18 (17 years and 364 days) years.

Exclusion criteria

Exclusion Criteria:

  • Subjects scheduled to have > 3 Lumbar Punctures over the course of the study treatment period
  • Prior history of documented DVT or PE in the past 3 months
  • Known inherited bleeding disorder or coagulopathy
  • Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open ] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.
  • Uncontrolled severe hypertension at enrollment. Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children
  • Extreme hyperleukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment
  • Liver dysfunction manifested by SGTP () > 5X (ULN) and/or Aspartate aminotransferase (AST) >5 X ULN and/or direct (conjugated) > 2X ULN
  • Renal function \< 30% of normal for age and size as determined by the Schwartz formula
  • (INR) > 1.4 and activated partial thromboplastin time (aPTT) > 3 seconds above the upper limit of normal for age, within 1 week prior to enrollment.
  • History of allergy to apixaban or Factor Xa inhibitors
  • History of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity
  • Any drug being administered during the study

Other protocol inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    Apixaban

    Children aged 1 to \<18 years weighing 6 to \<35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days. Children aged 1 to \<18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects \< 5years and \< 35 kg may be administered 0.5-mg tablets only

    Drug: Apixaban

  • Placebo comparator
    No systemic anticoagulant prophylaxis

    No systemic anticoagulant prophylaxis

    Other: No systemic anticoagulant prophylaxis

Interventions

  • OtherNo systemic anticoagulant prophylaxis
06

What researchers measure

Primary outcomes

  1. The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death

    The number of participants with non-fatal deep vein thromboses (DVT) (including asymptomatic and symptomatic), pulmonary embolism (PE), cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE) related-death objectively confirmed by a blinded, independent adjudication committee. Symptomatic events are included during the intended treatment period. Asymptomatic events are included from scans up to Day 40.

    Time frame: From first dose up to approximately 40 days after first dose

  2. The Number of Participants With Adjudicated Major Bleeding

    The number of participants with major bleeding adjudicated by a blinded, independent adjudication committee. Adjudicated major bleeding is defined as bleeding that satisfies one or more of the following criteria: 1. fatal bleeding 2. clinically overt bleeding associated with a decrease in hemoglobin of at least 20g/L (ie, 2g/dL) in a 24-hour period 3. bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS; and/or 4. bleeding that requires surgical intervention in an operating suite, including interventional radiology.

    Time frame: From first dose up to approximately 34 days after first dose

Secondary outcomes

  1. The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)

    The number of participants with non-fatal asymptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 40 days after first dose

  2. The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)

    The number of participants with non-fatal symptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  3. The Number of Participants With Non-fatal Pulmonary Embolism (PE)

    The number of participants with non-fatal pulmonary embolism (PE) adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  4. The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)

    The number of participants with cerebral venous sinus thrombosis (CVST) adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  5. The Number of Participants With Venous Thromboembolism (VTE)-Related-death

    The number of participants with venous thromboembolism (VTE)-related-death adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  6. The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)

    The number of participants with major and clinically relevant non-major bleeding (CRNMB) adjudicated by a blinded, independent adjudication committee CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

    Time frame: From first dose up to approximately 34 days after first dose

  7. The Number of Participant Deaths

    The number of participant deaths adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose date until the end of the treatment period + 30 days (Up to approximately 59 days)

  8. The Number of Participants With an Arterial Thromboembolic Event

    The number of participants with an arterial thromboembolic event including paradoxical embolism and stroke adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  9. The Number of Participants With a CVAD-Related Infection

    The number of participants with a central venous access device (CVAD)-related infection adjudicated by a blinded, independent adjudication committee

    Time frame: From first dose up to approximately 34 days after first dose

  10. The Number of Participants Needing Catheter Replacements During the Study

    The number of participants needing catheter replacements during the study

    Time frame: From first dose up to approximately 34 days after first dose

  11. The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use

    The number of participants with central venous access device (CVAD) patency restoration events after thrombolytic therapy use

    Time frame: From first dose up to approximately 34 days after first dose

  12. The Number Participants Experiencing Superficial Vein Thrombosis Events

    The number participants experiencing superficial vein thrombosis events. Clots that occur in a superficial vein ie, cephalic vein, basilic vein (upper extremity) or saphenous vein (lower extremity) confirmed by radiographic imaging.

    Time frame: From first dose up to approximately 34 days after first dose

  13. The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)

    The number of participants with clinically relevant non-major bleeding events (CRNMB) adjudicated by a blinded, independent adjudication committee. CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

    Time frame: From first dose up to approximately 34 days after first dose

  14. The Number of Participants With Minor Bleeding Events

    The number of participants with minor bleeding events adjudicated by a blinded, independent adjudication committee. Minor bleeding defined as any overt or macroscopic evidence of bleeding that does not fulfill the criteria for either major bleeding or CRNMB

    Time frame: From first dose up to approximately 34 days after first dose

  15. The Number of Platelet Transfusions Needed During the Study

    The number of platelet transfusions needed during the study. The events are not adjudicated. A subject could have more than one platelet transfusion.

    Time frame: From first dose up to approximately 34 days after first dose

  16. Maximum Observed Concentration (Cmax)

    The maximum observed concentration (Cmax) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

    Time frame: pre-dose, 1-4 hours post dose

  17. Trough Observed Concentration (Cmin)

    The trough observed concentration (Cmin) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

    Time frame: pre-dose, 1-4 hours post dose

  18. Area Under the Concentration-Time Curve [AUC(TAU)]

    The area under the concentration-time curve \[AUC(TAU)\] was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

    Time frame: pre-dose, 1-4 hours post dose

  19. Anti-FXa Activity

    Anti-FXa Activity was measured to characterize the relationship between apixaban plasma concentration and anti-FXa activity in pediatric subjects receiving induction chemotherapy

    Time frame: pre-dose and 2.5 hours after dosing on day 7. Day 8 and day 15.

07

Results

Posted Mar 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneApixabanStandard of Care
Started256256
Adverse event analysis population250262
Completed242249
Not completed147
Withdrew: Lost to follow-up01
Withdrew: Administrative reason by sponsor01
Withdrew: Death12
Withdrew: Participant withdrew consent133

Outcome measures

PrimaryThe Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death

The number of participants with non-fatal deep vein thromboses (DVT) (including asymptomatic and symptomatic), pulmonary embolism (PE), cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE) related-death objectively confirmed by a blinded, independent adjudication committee. Symptomatic events are included during the intended treatment period. Asymptomatic events are included from scans up to Day 40.

Time frame:
From first dose up to approximately 40 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death
ParticipantsApixabanStandard of Care
The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death3145
Statistical analysis
  • Apixaban vs Standard of Care · Cochran-Mantel-Haenszel · p = 0.0403
PrimaryThe Number of Participants With Adjudicated Major Bleeding

The number of participants with major bleeding adjudicated by a blinded, independent adjudication committee. Adjudicated major bleeding is defined as bleeding that satisfies one or more of the following criteria: 1. fatal bleeding 2. clinically overt bleeding associated with a decrease in hemoglobin of at least 20g/L (ie, 2g/dL) in a 24-hour period 3. bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS; and/or 4. bleeding that requires surgical intervention in an operating suite, including interventional radiology.

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Adjudicated Major Bleeding
ParticipantsApixabanStandard of Care
The Number of Participants With Adjudicated Major Bleeding22
Statistical analysis
  • Apixaban vs Standard of Care · Cochran-Mantel-Haenszel · p = 1.0000
SecondaryThe Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)

The number of participants with non-fatal asymptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 40 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)
ParticipantsApixabanStandard of Care
The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)2738
SecondaryThe Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)

The number of participants with non-fatal symptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)
ParticipantsApixabanStandard of Care
The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)46
SecondaryThe Number of Participants With Non-fatal Pulmonary Embolism (PE)

The number of participants with non-fatal pulmonary embolism (PE) adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Non-fatal Pulmonary Embolism (PE)
ParticipantsApixabanStandard of Care
The Number of Participants With Non-fatal Pulmonary Embolism (PE)00
SecondaryThe Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)

The number of participants with cerebral venous sinus thrombosis (CVST) adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)
ParticipantsApixabanStandard of Care
The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)01
SecondaryThe Number of Participants With Venous Thromboembolism (VTE)-Related-death

The number of participants with venous thromboembolism (VTE)-related-death adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Venous Thromboembolism (VTE)-Related-death
ParticipantsApixabanStandard of Care
The Number of Participants With Venous Thromboembolism (VTE)-Related-death00
SecondaryThe Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)

The number of participants with major and clinically relevant non-major bleeding (CRNMB) adjudicated by a blinded, independent adjudication committee CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)
ParticipantsApixabanStandard of Care
The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)135
SecondaryThe Number of Participant Deaths

The number of participant deaths adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose date until the end of the treatment period + 30 days (Up to approximately 59 days)
Reported as:
Count of participants · Participants
The Number of Participant Deaths
ParticipantsApixabanStandard of Care
The Number of Participant Deaths13
SecondaryThe Number of Participants With an Arterial Thromboembolic Event

The number of participants with an arterial thromboembolic event including paradoxical embolism and stroke adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With an Arterial Thromboembolic Event
ParticipantsApixabanStandard of Care
The Number of Participants With an Arterial Thromboembolic Event00
SecondaryThe Number of Participants With a CVAD-Related Infection

The number of participants with a central venous access device (CVAD)-related infection adjudicated by a blinded, independent adjudication committee

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With a CVAD-Related Infection
ParticipantsApixabanStandard of Care
The Number of Participants With a CVAD-Related Infection16
SecondaryThe Number of Participants Needing Catheter Replacements During the Study

The number of participants needing catheter replacements during the study

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants Needing Catheter Replacements During the Study
ParticipantsApixabanStandard of Care
The Number of Participants Needing Catheter Replacements During the Study32
SecondaryThe Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use

The number of participants with central venous access device (CVAD) patency restoration events after thrombolytic therapy use

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use
ParticipantsApixabanStandard of Care
The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use00
SecondaryThe Number Participants Experiencing Superficial Vein Thrombosis Events

The number participants experiencing superficial vein thrombosis events. Clots that occur in a superficial vein ie, cephalic vein, basilic vein (upper extremity) or saphenous vein (lower extremity) confirmed by radiographic imaging.

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number Participants Experiencing Superficial Vein Thrombosis Events
ParticipantsApixabanStandard of Care
The Number Participants Experiencing Superficial Vein Thrombosis Events42
SecondaryThe Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)

The number of participants with clinically relevant non-major bleeding events (CRNMB) adjudicated by a blinded, independent adjudication committee. CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)
ParticipantsApixabanStandard of Care
The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)113
SecondaryThe Number of Participants With Minor Bleeding Events

The number of participants with minor bleeding events adjudicated by a blinded, independent adjudication committee. Minor bleeding defined as any overt or macroscopic evidence of bleeding that does not fulfill the criteria for either major bleeding or CRNMB

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants With Minor Bleeding Events
ParticipantsApixabanStandard of Care
The Number of Participants With Minor Bleeding Events3720
SecondaryThe Number of Platelet Transfusions Needed During the Study

The number of platelet transfusions needed during the study. The events are not adjudicated. A subject could have more than one platelet transfusion.

Time frame:
From first dose up to approximately 34 days after first dose
Reported as:
Number · Platelet Transfusions
The Number of Platelet Transfusions Needed During the Study
Platelet TransfusionsApixabanStandard of Care
The Number of Platelet Transfusions Needed During the Study266248
SecondaryMaximum Observed Concentration (Cmax)

The maximum observed concentration (Cmax) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

Time frame:
pre-dose, 1-4 hours post dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax)
ng/mLParticipants Weight Range ≥ 35 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 10.5 to < 18 kg
Maximum Observed Concentration (Cmax)56.5 ± 36.563.6 ± 38.661.4 ± 43.954.2 ± 46.8
SecondaryTrough Observed Concentration (Cmin)

The trough observed concentration (Cmin) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

Time frame:
pre-dose, 1-4 hours post dose
Reported as:
Geometric mean · ng/mL
Trough Observed Concentration (Cmin)
ng/mLParticipants Weight Range ≥ 35 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 10.5 to < 18 kg
Trough Observed Concentration (Cmin)18.8 ± 57.818.1 ± 97.412 ± 14212.9 ± 113
SecondaryArea Under the Concentration-Time Curve [AUC(TAU)]

The area under the concentration-time curve \[AUC(TAU)\] was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.

Time frame:
pre-dose, 1-4 hours post dose
Reported as:
Geometric mean · ng•h/mL
Area Under the Concentration-Time Curve [AUC(TAU)]
ng•h/mLParticipants Weight Range ≥ 35 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 10.5 to < 18 kg
Area Under the Concentration-Time Curve [AUC(TAU)]470 ± 35.3510 ± 42.7453 ± 44.8416 ± 48.5
SecondaryAnti-FXa Activity

Anti-FXa Activity was measured to characterize the relationship between apixaban plasma concentration and anti-FXa activity in pediatric subjects receiving induction chemotherapy

Time frame:
pre-dose and 2.5 hours after dosing on day 7. Day 8 and day 15.
Reported as:
Mean · Anti-FXa activity (ng/mL)
Anti-FXa Activity
Anti-FXa activity (ng/mL)Participants Weight Range ≥ 35 kgParticipants Weight Range 25 to < 35 kgParticipants Weight Range 18 to < 25 kgParticipants Weight Range 10.5 to < 18 kg
Day 7 (Predose)55.3 ± 16.462.2 ± 19.452.8 ± 1644.2 ± 12.9
Day 7 (2.5 hours)78.7 ± 28.872.1 ± 30.677.5 ± 30.887.5 ± 45.5
Day 855.2 ± 8.96—47.5 ± 10.648 ± 11.3
Day 1570.2 ± 2875.3 ± 33.963.9 ± 21.664.8 ± 25.3

Adverse events

Collected over AEs are collected from the first dose date until the end of the treatment period + 2 days (Up to approximately 31 days) SAEs are collected from the first dose date until the end of the treatment period + 30 days (Up to approximately 59 days). All Cause Mortality was collected from first dose up to DBL date: Sep-13-2021 (up to approximately 6 years.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban1/250 (0.4%)91/250 (36.4%)204/250 (81.6%)
Standard of Care4/262 (1.5%)83/262 (31.7%)193/262 (73.7%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventApixabanStandard of Care
Febrile neutropeniaBlood and lymphatic system disorders15/25016/262
EmbolismVascular disorders9/2503/262
PyrexiaGeneral disorders7/2507/262
SepsisInfections and infestations6/2505/262
Deep vein thrombosisVascular disorders2/2506/262
ColitisGastrointestinal disorders2/2505/262
ConstipationGastrointestinal disorders1/2505/262
HyperglycaemiaMetabolism and nutrition disorders4/2502/262
DehydrationMetabolism and nutrition disorders1/2504/262
Device related infectionInfections and infestations3/2502/262
Most frequent other events
Showing 10 of 33
Most frequent other events
EventApixabanStandard of Care
AnaemiaBlood and lymphatic system disorders85/25088/262
ConstipationGastrointestinal disorders58/25050/262
Platelet count decreasedInvestigations54/25055/262
Alanine aminotransferase increasedInvestigations46/25039/262
Abdominal painGastrointestinal disorders34/25048/262
HyponatraemiaMetabolism and nutrition disorders36/25030/262
HypoalbuminaemiaMetabolism and nutrition disorders29/25034/262
Back painMusculoskeletal and connective tissue disorders29/25019/262
HyperglycaemiaMetabolism and nutrition disorders19/25030/262
ThrombocytopeniaBlood and lymphatic system disorders28/25025/262

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ApixabanStandard of CareTotal
Mean7.2 ± 4.347.1 ± 4.397.2 ± 4.36
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanStandard of CareTotal
Female115107222
Male141149290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApixabanStandard of CareTotal
Hispanic or Latino5963122
Not Hispanic or Latino196192388
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ApixabanStandard of CareTotal
American Indian or Alaska Native112
Asian252752
Native Hawaiian or Other Pacific Islander101
Black or African American121224
White194194388
More than one race000
Unknown or Not Reported232245
08

Study locations

96 sites
  • Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr.
    Phoenix, Arizona 85016, United States
  • City of Hope
    Duarte, California 91010, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92350, United States
  • Childrens Hospital Of La
    Los Angeles, California 90027, United States
  • Children'S Hospital Of Orange County
    Orange, California 92868, United States
  • Lucile Packard Children's Hospital (LPCH)
    Palo Alto, California 94304, United States
  • Rady Children'S Hospital - San Diego
    San Diego, California 92123-4282, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06520, United States
  • Nemours / A. I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Golisano Childrens Hospital of Southwest Florida
    Fort Myers, Florida 33908, United States
  • Shands Hospital At University Of Florida
    Gainesville, Florida 32610-0298, United States
  • Nemours Children'S Clinic
    Jacksonville, Florida 32207, United States
  • Nemours Children'S Clinic - Orlando
    Orlando, Florida 32827, United States
  • Nemours Children'S Clinic-Pensacola
    Pensacola, Florida 32504, United States
  • All Childrens Hospital Specialty Physicians
    Saint Petersburg, Florida 33701, United States
  • St. Marys Medical Center
    West Palm Beach, Florida 33407, United States
  • Childrens Healthcare Of Atlanta - E
    Atlanta, Georgia 30342, United States
  • Navicent Health Physician Group
    Macon, Georgia 31201, United States
  • St. Luke'S Mountain State Tumor Institute
    Boise, Idaho 83712, United States
  • Children'S Center For Cancer And Blood Diseases
    Indianapolis, Indiana 46260, United States
  • Blank Childrens Hospital
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kentucky
    Lexington, Kentucky 40536-0293, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Childrens Hospital New Orleans
    New Orleans, Louisiana 70118, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Sinai Hospital Of Baltimore
    Baltimore, Maryland 21215, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University Of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Childrens Hospitals And Clinics Of Minnesota
    Minneapolis, Minnesota 55404, United States
  • University Of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • University Of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Valerie Fund Children's Center at St. Joseph's Children's Hospital
    Paterson, New Jersey 07503, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • University Of Rochester General Clinical Research Center
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Unv. Of Nc At Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Akron Children'S Hospital
    Akron, Ohio 44308, United States
  • Cincinnati Children'S Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • University Hospitals
    Cleveland, Ohio 44106, United States
  • Nationwide Children'S Hospital
    Columbus, Ohio 43205, United States
  • Lehigh Valley Hospital - Muhlenberg
    Bethlehem, Pennsylvania 18017, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital Of Pittsburgh Of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Hospital at TriStar Centennial
    Nashville, Tennessee 37203, United States
  • Monroe Carell Jr Children'S Hosp. At Vanderbilt Tower
    Nashville, Tennessee 37232, United States
  • Dell Children'S Medical Center Of Central Texas
    Austin, Texas 78723, United States
  • Driscoll Children'S Hospital
    Corpus Christi, Texas 78411, United States
  • Texas Children's Cancer and Hematology Centers
    Houston, Texas 77030, United States
  • Children's Hospital of San Antonio
    San Antonio, Texas 78207, United States
  • University Hospital
    San Antonio, Texas 78284, United States
  • Scott & White - McLane Children's Specialty Clinic
    Temple, Texas 76502, United States
  • Providence Sacred Heart Medical Center
    Spokane, Washington 99204, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    New Lambton Heights, New South Wales 2305, Australia
  • Queensland Children's Hospital
    Sth Brisbane, Queensland 4101, Australia
  • Monash Medical Centre Clayton
    Clayton, Victoria 3168, Australia
  • Local Institution
    Parkville, Victoria 3052, Australia
  • Local Institution
    Bruxelles, 1020, Belgium
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Edegem, 2650, Belgium
  • Local Institution
    Gent, 9000, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Local Institution
    Edmonton, Alberta T6G 2B7, Canada
  • Local Institution
    St, John's, Newfoundland and Labrador A1B 3V6, Canada
  • Children'S Hospital London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Children'S Hospital Of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Klinika detske onkologie
    Brno, 613 00, Czechia
  • Local Institution
    Budapest, 1094, Hungary
  • Local Institution
    Debrecen, 4032, Hungary
  • Local Institution
    Pecs, 7623, Hungary
  • Local Institution
    Seoul, 03080, Korea, Republic of
  • Local Institution
    Seoul, 03722, Korea, Republic of
  • Local Institution
    Df, Distrito Federal 04530, Mexico
  • Local Institution
    Guadalajara, Jalisco 44340, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Christchurch, 8011, New Zealand
  • Klinika Transplantacji Szpiku Onkologii i Hematologii Dzieciecej
    Wroclaw, 50-556, Poland
  • Oddzial Hematologii i Onkologii Dzieciecej
    Zabrze, 41-800, Poland
  • Local Institution
    Caguas, 00725, Puerto Rico
  • Local Institution
    Kirov, 610027, Russian Federation
  • Local Institution
    Moscow, 115478, Russian Federation
  • Local Institution
    Moscow, 117198, Russian Federation
  • Local Institution
    Saint Petersburg, 197758, Russian Federation
  • Local Institution
    St.petersburg, 197341, Russian Federation
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jul 2021, 68 months.

Results were first posted in Mar 2022, 8 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 68 months is above that.

Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2015
First posted
Feb 24, 2015
StartActual
Oct 22, 2015
Primary completionActual
Jul 7, 2021
CompletionActual
Jul 7, 2021
Results first posted
Mar 8, 2022
Last update
Mar 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02369653
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 24, 2015
Start date
Oct 22, 2015
Primary completion
Jul 7, 2021
Completion
Jul 7, 2021
Results posted
Mar 8, 2022
Last update
Mar 8, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion